Connect with us

Health

High Mercury Levels in Canned Tuna Across Europe Spark Health Concerns

Published

on

A recent report by marine conservation NGO Bloom and consumer advocacy group Foodwatch reveals elevated mercury levels in canned tuna across Europe, raising new concerns about public health risks. Analyzing nearly 150 tuna cans from Germany, the United Kingdom, Spain, France, and Italy, the NGOs found that every sample contained mercury, with 57% surpassing the 0.3 parts per million (ppm) mercury limit imposed on other types of fish.

The findings have fueled a call for stronger regulations in Europe to address mercury levels in tuna. Currently, the European standard for mercury in tuna is set at a maximum of 1 ppm—more lenient than the threshold for other fish. “The tuna industry’s influence has set these lenient standards, but we won’t give up until we achieve more protective regulations,” stated Karine Jacquemart, CEO of Foodwatch France.

Concerns Over Health Impacts

Mercury, particularly in the form of methylmercury, is classified by the World Health Organization (WHO) as a potential carcinogen, posing significant risks, especially to vulnerable groups. The European Food Safety Authority (EFSA) set the tolerable weekly intake (TWI) for methylmercury at 1.3 micrograms per kilogram of body weight in 2012, double the TWI set in the United States. Given these limits, Bloom researcher Julie Guterman warns that even a single portion of canned tuna could exceed safe levels for consumers over 79 kg.

“Methylmercury is a neurotoxin that harms nervous tissue and affects cognitive development in unborn children and young children,” explained Dr. Philippe Grandjean, a professor in environmental medicine, in a statement. Prolonged exposure to methylmercury can impact memory, language, and motor skills, as well as fine motor and spatial vision.

See also  WHO Urges Global Overhaul of School Food to Combat Childhood Obesity

The phenomenon of bioaccumulation explains why tuna and other high-food-chain species like swordfish and sharks are particularly susceptible to mercury contamination. Mercury, a byproduct of natural occurrences like volcanic eruptions and human activities such as coal combustion, becomes more toxic when it interacts with ocean bacteria, transforming into methylmercury. As tuna consume smaller fish, they accumulate methylmercury, passing it up the food chain to consumers.

Calls for Change and Consumer Protection

Bloom and Foodwatch have launched an initiative calling for the reduction of the tuna mercury threshold to 0.3 ppm. They’ve also initiated a petition targeting major European retailers—including Carrefour, Lidl, and Edeka—urging them to remove high-mercury tuna products from their shelves and to raise awareness of the health risks for consumers.

In response, the European Commission defended its current regulations, noting that maximum mercury levels for fish are set “as low as reasonably achievable” based on real-world data. Officials also argued that lowering the threshold further could disrupt the food supply.

As consumer advocacy groups continue to push for stricter guidelines, the Commission says it will monitor scientific advancements to ensure European food safety standards remain up-to-date. For now, however, Bloom and Foodwatch warn that with the European average consumption of tuna exceeding 2.8 kilograms per person annually, awareness and caution are essential when it comes to dietary choices involving tuna.

Health

Study Finds Men Far More Likely Than Women to ‘Hit the Wall’ in Marathons

Published

on

Men are significantly more likely than women to experience the dreaded marathon phenomenon known as “hitting the wall,” according to a large international study that analysed the performances of more than 870,000 runners over a 26-year period.

The research, published in the journal Scientific Reports, examined the results of 873,334 finishers in the Berlin Marathon between 1999 and 2025. Researchers found that although men generally complete marathons faster than women, they are much more likely to suffer a dramatic slowdown during the later stages of the race because of less consistent pacing.

According to the study, men are almost twice as likely overall to experience a sudden decline in speed during a marathon. In some performance categories, they were found to be up to six times more likely than women to “hit the wall,” a term commonly used to describe severe physical exhaustion caused by depleted energy stores.

Researchers said the findings point to differences in race strategy rather than physical ability alone. Men were more likely to begin races at an aggressive pace, increasing the risk of fatigue before reaching the finish line.

The study concluded that “men, regardless of performance level, are more prone to aggressive pacing and catastrophic deceleration.” The authors suggested that greater willingness to take risks and higher levels of confidence may encourage many male runners to start faster than they can realistically sustain over the full 42.195-kilometre distance.

Women, on the other hand, displayed more controlled pacing throughout the race. Researchers found they were better at regulating their effort from start to finish, reducing the likelihood of a significant loss of speed during the closing kilometres.

See also  Twice-Yearly HIV Prevention Jab Clears Major Hurdle in Europe

The report described women as showing “superior self-pacing abilities and greater resistance to decision-making fatigue,” characteristics that can be particularly valuable during endurance events.

Maintaining a steady pace is widely regarded as one of the most important factors in marathon performance. Running too quickly during the opening stages can rapidly consume the body’s glycogen reserves, leaving athletes without enough energy to sustain their speed in the final part of the race.

The researchers noted that pacing is “the most critical tactical determinant of performance” in marathon running, making strategic decision-making just as important as physical fitness.

The findings could influence how coaches and runners prepare for long-distance races. Rather than focusing solely on speed, the study suggests that adopting a realistic race plan and maintaining a consistent pace throughout the event may improve overall performance and reduce the chances of a late-race collapse.

With marathon participation continuing to grow worldwide, the researchers believe a better understanding of pacing strategies could help runners of all abilities achieve stronger and more consistent results.

Continue Reading

Health

Study Links Higher Coffee Consumption to Lower Risk of Liver Disease

Published

on

Regular coffee consumption may help reduce the risk of serious liver diseases, including cirrhosis, liver cancer and liver-related deaths, according to a new study published in the journal Clinical Gastroenterology and Hepatology.

The research found that people who consumed higher amounts of coffee, including decaffeinated varieties, were less likely to develop chronic liver conditions than those who drank little or no coffee. The findings add to growing evidence that coffee may play a role in supporting long-term liver health, although researchers stressed that the results do not prove a direct cause-and-effect relationship.

The study examined data from more than 350,000 participants enrolled in the UK Biobank, one of the world’s largest long-term health research projects. None of the participants had cirrhosis or liver cancer at the beginning of the study. Researchers monitored their health over a period of 13 years to assess how coffee consumption affected liver-related outcomes.

According to the findings, participants who drank five or more cups of coffee each day had a 32 percent lower risk of developing cirrhosis than those who consumed little or no coffee. They also recorded a 47 percent lower risk of liver cancer and a 42 percent reduction in deaths linked to liver disease.

Researchers found additional indicators of improved liver health among regular coffee drinkers. Participants with higher coffee intake showed lower levels of liver fat, liver iron, fibrosis and inflammation. Blood tests also revealed increased levels of proteins associated with healthy liver function, while markers linked to liver scarring and inflammation were generally lower.

The findings come as liver disease continues to pose a major global health challenge. A separate study published in 2023 estimated that liver disease causes around two million deaths each year, accounting for about four percent of all deaths worldwide. Men account for nearly two-thirds of those fatalities.

See also  Air Pollution Linked to 239,000 Deaths in Europe, Highlighting Regional Disparities

Despite the encouraging results, the researchers urged caution in interpreting the findings. Senior study author Ju Dong Yang said moderate coffee consumption appears to be beneficial for people who already enjoy drinking coffee and tolerate it well.

“Our findings support moderate coffee consumption for people who already enjoy and tolerate it well,” Yang said.

He added that the study does not provide sufficient evidence to recommend that people who do not currently drink coffee should begin doing so solely to reduce their risk of liver disease.

Health experts continue to advise that maintaining a healthy weight, limiting alcohol consumption, eating a balanced diet and managing conditions such as obesity and diabetes remain the most effective ways to reduce the risk of chronic liver disease. Researchers said additional studies are needed to better understand which compounds in coffee may contribute to its potential protective effects.

Continue Reading

Health

Lancet Review Finds mRNA Vaccines Safe and Highly Effective, Calls for Wider Global Access

Published

on

A comprehensive review of data covering billions of administered doses of mRNA vaccines has concluded that the technology remains both safe and highly effective in preventing infectious diseases, with researchers urging governments and health organisations to focus on expanding global access.

The review, published in The Lancet, examined evidence gathered since mRNA vaccines were first deployed on a large scale during the COVID-19 pandemic. Researchers found that the vaccines continue to provide strong protection against severe illness while serious side effects remain uncommon.

Unlike conventional vaccines, mRNA vaccines work by delivering genetic instructions that enable the body’s cells to produce a harmless viral protein. This process trains the immune system to recognise and respond to future infections without altering a person’s DNA.

According to the review, mRNA vaccines were 87% effective in preventing confirmed SARS-CoV-2 infections within 14 to 42 days after vaccination. The vaccines also demonstrated 93% effectiveness in preventing hospital admissions and 94% effectiveness in preventing deaths related to COVID-19 during the same period.

Researchers noted that immunity declines over time, but booster doses restore a significant portion of the lost protection.

The review also assessed vaccine safety across billions of administered doses. It found that serious adverse events, including myocarditis, pericarditis and anaphylaxis, occurred very rarely. Most reported reactions, such as pain at the injection site, fatigue and fever, were mild to moderate and typically resolved within a few days.

“Across billions of administered doses, serious adverse events have been rare, well characterised, and consistently outweighed by the substantial protection conferred against severe disease, hospitalisation, and death,” the researchers wrote.

See also  Ukraine's Healthcare Reforms Align with EU Standards Amid Ongoing War, Says WHO Official

The review concluded that the vaccines have proven effective across a broad range of populations, including children, older adults, pregnant women and people with weakened immune systems.

Researchers also highlighted the growing potential of mRNA technology beyond infectious diseases. They said ongoing research could lead to personalised cancer vaccines designed to match an individual patient’s tumour characteristics, opening new possibilities for targeted treatment.

Co-author Manish Sadarangani of the University of British Columbia and BC Children’s Hospital Research Institute said mRNA vaccines have already changed how the world responds to emerging infectious diseases and could continue to play an important role in preventive medicine and cancer care.

The review also noted that improvements in vaccine storage, including higher-temperature storage methods and freeze-drying technologies, could simplify transportation, reduce waste and improve access in remote regions.

Despite these advances, the researchers stressed that manufacturing capacity and equitable distribution remain major challenges. They called for greater investment in local production, technology transfer and stronger regulatory systems, particularly in low- and middle-income countries.

Co-author Robin Shattock of Imperial College London said expanding manufacturing networks and strengthening regional production capabilities would shorten supply chains, lower costs and help ensure countries have faster access to vaccines during future global health emergencies.

Continue Reading

Trending